• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

28.90 +4.78 (+19.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
May 01, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
April 27, 2026
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease -- 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces CFO Succession Plan
April 16, 2026
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 03, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
March 02, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
February 25, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
February 20, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
February 02, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 06, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
October 23, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 07, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
July 08, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
June 27, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
May 28, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
May 13, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
May 01, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
April 28, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
April 01, 2025
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
March 18, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
March 14, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
March 04, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
March 03, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
February 07, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
February 06, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
January 03, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
December 20, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
December 17, 2024
Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE® 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
November 25, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 12, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap